Pharmaceutical
Pharmaceutical manufacturing operates in a regulatory environment where the integrity of utility systems directly impacts product quality and patient safety. Clean utility systems — WFI, Purified Water, Clean Steam, and CIP circuits — must maintain material and surface finish standards that prevent biofilm formation and particulate contamination. Every change and inspection must produce validation-ready documentation that satisfies FDA, EMA, and MHRA auditors.
Applicable Standards
Critical focus areas
- Clean utility and sanitary systems integrity
- ASME BPE compliance and surface finish (Ra) tracking
- Sterilization-in-place (SIP) fatigue monitoring
- Designed to support 21 CFR Part 11 workflows (audit trail, e-signatures); no third-party certification
- GMP-compliant change control with validation impact assessment
Key Challenges
- Stringent cleanliness standards with zero defect tolerance
- Validation and GxP requirements for every inspection and change
- Complex multi-product changeovers affecting corrosion exposure profiles
- FDA and EMA audit readiness on demand
Active damage mechanisms
Reliatic ships with a pre-loaded damage mechanism library for Pharmaceutical. Each mechanism is linked to its relevant inspection techniques, examination intervals, and regulatory acceptance criteria.
Rouge Formation
Iron oxide contamination on stainless steel surfaces in high-purity water systems — Class I (surface), Class II (systemic), and Class III (high-temperature) rouge degrading water quality.
Microbiologically Influenced Corrosion (MIC)
Biofilm-associated pitting in stainless steel systems with dead legs, low-flow zones, or inadequate sanitization, compromising both material integrity and product sterility.
Intergranular Corrosion (Sensitization)
Weld decay in austenitic stainless steel heat-affected zones where improper welding procedure causes chromium carbide precipitation, creating corrosion-susceptible grain boundaries.
Crevice Corrosion at Gasket Interfaces
Localized corrosion in oxygen-depleted crevices at flange faces, threaded connections, and under gaskets — particularly critical in chloride-containing CIP solutions.
Electropolish Degradation
Progressive deterioration of electropolished surface finish (Ra values) from repeated CIP/SIP cycles, chemical attack, or mechanical damage, increasing biofilm attachment risk.
Platform Configuration for Pharmaceutical
Outcome
Maintain continuous audit readiness with zero tolerance for undocumented changes, generating validation-ready evidence packages that satisfy FDA, EMA, and MHRA inspectors on demand.